Short Bowel Syndrome Market By Drug Type (GLP-2, Glutamine, Growth Hormones, Other Drugs) - Growth, Future Prospects, And Competitive Analysis, 2015 -2025

A short bowel syndrome is a group of complex diseases that occur due to the malfunction of a portion of the small and/or large intestine. Individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals, and other vital elements, which leads to malnutrition and weight loss.

The report titled "Global Short Bowel Syndrome Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the Short Bowel Syndrome market along with the market size and estimates for the duration of 2017 to 2025. The research study covers an in-depth analysis of market segments based on drug type and different geographical regions.

In order to help strategic decision-makers, the report also includes sections on the competitive profiling of the leading players in the global short bowel syndrome market, an attractive investment proposition, and the market positioning of key manufacturers.

Geographically, the global short bowel syndrome market is studied for the following regional markets:

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia-Pacific
• China
• Japan
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• rest of Latin America
• Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Pipeline analysis, market inclination insights, and drivers, challenges, and opportunities aid readers in understanding current trends in the global short bowel syndrome market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global short bowel syndrome market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global short bowel syndrome market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global short bowel syndrome market, offering market size and estimates for the period from 2017 to 2025, keeping in mind the above-mentioned factors.

Based on the type of drug, the nonalcoholic steatohepatitis market is segmented into:

• GLP-2
• Glutamine
• Growth Hormone
• Others

A short bowel syndrome is a group of complex diseases that occur due to the malfunction of a portion of the small and/or large intestine. Individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals, and other vital elements, which leads to malnutrition and weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling, and life-threatening complications. There is no particular cure for this disorder; however, surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury, or trauma to the small intestine.

Such complications are making a significant contribution to the growth of the short bowel syndrome market. On the basis of drugs, the market is segmented into GLP-2, glutamine, growth hormone, and others. GLP-2 currently has the largest drug market in the short bowel syndrome market, as it is marketed under the brand names Gattex and Revestive in the United States and Europe, respectively. The drugs currently hold orphan drug status, and the exclusivity of the drugs in the treatment of short bowel syndrome would further draw huge revenue during the forecast period.

For the purpose of this study, the global short bowel syndrome market is categorized as follows:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

For the purpose of this study, the global short bowel syndrome market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the largest market in the short bowel syndrome market, with the U.S. being the highest-grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approved drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine is further driving the short bowel market in the U.S. Europe held the second-largest market, as in the U.S., approximately 6,000–7,000 SBS patients are dependent on parenteral support, with a similar prevalence in Europe. Revive is the highest-grossing drug in Europe and is marketed by Shire plc. Moreover, an efficient reimbursement scenario in North America and Europe would further drive the market for short-bowel syndrome during the forecast period.

Frequently Asked Questions: